[Management of hypertension in non-dialysis and dialysis patients with chronic kidney disease: Chinese expert consensus].

Chronic kidney disease (CKD) is a global public health problem that is usually progressive. Hypertension is a risk factor for the progression of CKD, and cardiovascular disease is the most common cause of death in patients with CKD. In Chinese patients with CKD, there is a high prevalence of hypertension and a poor rate of control. Several studies have demonstrated that effective blood pressure control can delay the progression of kidney disease and reduce the risk of cardiovascular events and all-cause mortality. Based on previously published high-quality evidence, guidelines and consensus reports, the Zhongguancun Nephropathy and Blood Purification Innovation Alliance formulated a new consensus. This consensus includes blood pressure measurement; the blood pressure management of non-dialysis patients, dialysis patients and kidney transplantation patients, and the interaction between commonly used drugs and antihypertensive drugs. The consensus aims to further strengthen the standardization and safety of blood pressure management in CKD patients, delay disease progression, reduce disease burden, and comprehensively improve the quality-of-life and prognosis of patients with CKD.慢性肾脏病（CKD）是一个全球性公共卫生问题，其通常呈进展性，高血压是CKD进展的危险因素，心血管疾病是导致CKD患者死亡的首位病因。我国CKD患者高血压患病率高，控制率低。近年来不断有研究证实，有效控制血压可延缓肾脏病进展，降低心血管事件和全因死亡风险。中关村肾病血液净化创新联盟基于已发表的高质量循证证据和既往指南/共识，针对CKD患者的血压管理提出较为详细的循证推荐，并形成本共识，内容包括CKD患者的血压测量、非透析患者的血压管理透析患者的血压管理、肾移植患者的血压管理及常用药物与降压药物的相互作用等，旨在进一步加强临床CKD患者血压管理的规范性和安全性，延缓疾病进展，减轻疾病负担，以提高患者生活质量，改善预后。.